+68.7%
QBTS vs MRNA
-15.1%
+83.8%
-96.7%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -3.1% | -3.4% | +0.3% | -2.8% |
| 7D | +3.8% | -10.1% | +13.9% | +4.9% |
| 30D | -15.2% | +126.7% | -141.9% | -29.6% |
| 3M | -27.2% | +184.1% | -211.3% | -42.7% |
| 6M | -10.1% | +143.3% | -153.4% | -26.7% |
| YTD | -34.5% | +359.9% | -394.4% | -53.6% |
| 1Y | +6.0% | +454.2% | -448.2% | -27.5% |
| 3Y | +1,779.3% | +26.0% | +1,753.3% | +1,390.9% |
| 5Y | +75.4% | -70.3% | +145.7% | +43.1% |
| All | +68.7% | -15.1% | +83.8% | +32.7% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling